360-OR: Hyperglucagonemia Reduces De Novo Lipogenesis and Increases Gluconeogenesis in Healthy Subjects

Although the effect of glucagon on glucose metabolism has been well characterized, its effect on lipid metabolism, particularly lipolysis and de novo lipogenesis, in humans in vivo has been poorly studied with controversial results. We examined the effect of short-term hyperglucagonemia on de novo l...

Full description

Saved in:
Bibliographic Details
Published inDiabetes (New York, N.Y.) Vol. 71; no. Supplement_1
Main Authors CHEN, XI, CARLI, FABRIZIA, PEZZICA, SAMANTHA, MOCCIARO, GABRIELE, CIOCIARO, DEMETRIO, GASTALDELLI, AMALIA, DEFRONZO, RALPH A., TRIPATHY, DEVJIT
Format Journal Article
LanguageEnglish
Published New York American Diabetes Association 01.06.2022
Subjects
Online AccessGet full text
ISSN0012-1797
1939-327X
DOI10.2337/db22-360-OR

Cover

Loading…
Abstract Although the effect of glucagon on glucose metabolism has been well characterized, its effect on lipid metabolism, particularly lipolysis and de novo lipogenesis, in humans in vivo has been poorly studied with controversial results. We examined the effect of short-term hyperglucagonemia on de novo lipogenesis (DNL) and endogenous glucose production (EGP) in 8 healthy normal glucose tolerant subjects (5M/3F, age=35±5, BMI= 24±1) who received a 12-hour (6PM to 6AM) glucagon infusion (6ng/kg/min) infusion with measurement of EGP (3-3H-glucose) on the following morning 6-AM. Subjects received deuterated water (D2O, 5g/kg fat free mass) at PM on the night prior to study. 8 weeks later subjects returned for a repeat study with 12-hour infusion of normal saline. DNL was quantified by measuring the incorporation of deuterated water into circulating triglycerides. Gluconeogenic rate was measured as (EGP) x (plasma C5/C2 glucose ratio) (EGP) x (plasma C5/C2 glucose ratio) . Plasma esterified and non-esterified FFA levels were measured with gas chromatography mass spectrometry (GC-MS) . Plasma glucagon increased from 57±3 to 219±21 pg/ml within one hour and remained elevated throughout the study. DNL was significantly decreased (1.64 ± 0.58% vs. 3.± 0.98%, p<0.05) after glucagon versus saline infusion. Both plasma palmitate (0.73 ± 0.vs. 0.67 ± 0.mmol/L) and total FFA (1.35 ± 0.vs. 1.21 ±0.mmol/L) concentrations were elevated after glucagon infusion (p<0.05) . EGP increased following glucagon infusion (2.13 ± 0.14 vs. 1.97± 0.11mg/kg/min, p =0.006) . The increase in EGP was primarily due to increased gluconeogenesis (1.48 ± 0.14 vs. 1.27 ± 0.11, p=0.02) , while the rate of glycogenolysis did not change (0.65± 0.14 vs. 0.70± 0.11, p=ns) . Conclusion: Short-term (12-hour) physiologic hyperglucagonemia in healthy subjects reduces hepatic de novo lipogenesis, stimulates adipose tissue lipolysis, and increases hepatic glucose production by increasing gluconeogenesis.
AbstractList Although the effect of glucagon on glucose metabolism has been well characterized, its effect on lipid metabolism, particularly lipolysis and de novo lipogenesis, in humans in vivo has been poorly studied with controversial results. We examined the effect of short-term hyperglucagonemia on de novo lipogenesis (DNL) and endogenous glucose production (EGP) in 8 healthy normal glucose tolerant subjects (5M/3F, age=35±5, BMI= 24±1) who received a 12-hour (6PM to 6AM) glucagon infusion (6ng/kg/min) infusion with measurement of EGP (3-3H-glucose) on the following morning 6-AM. Subjects received deuterated water (D2O, 5g/kg fat free mass) at PM on the night prior to study. 8 weeks later subjects returned for a repeat study with 12-hour infusion of normal saline. DNL was quantified by measuring the incorporation of deuterated water into circulating triglycerides. Gluconeogenic rate was measured as (EGP) x (plasma C5/C2 glucose ratio) (EGP) x (plasma C5/C2 glucose ratio) . Plasma esterified and non-esterified FFA levels were measured with gas chromatography mass spectrometry (GC-MS) . Plasma glucagon increased from 57±3 to 219±21 pg/ml within one hour and remained elevated throughout the study. DNL was significantly decreased (1.64 ± 0.58% vs. 3.± 0.98%, p<0.05) after glucagon versus saline infusion. Both plasma palmitate (0.73 ± 0.vs. 0.67 ± 0.mmol/L) and total FFA (1.35 ± 0.vs. 1.21 ±0.mmol/L) concentrations were elevated after glucagon infusion (p<0.05) . EGP increased following glucagon infusion (2.13 ± 0.14 vs. 1.97± 0.11mg/kg/min, p =0.006) . The increase in EGP was primarily due to increased gluconeogenesis (1.48 ± 0.14 vs. 1.27 ± 0.11, p=0.02) , while the rate of glycogenolysis did not change (0.65± 0.14 vs. 0.70± 0.11, p=ns) . Conclusion: Short-term (12-hour) physiologic hyperglucagonemia in healthy subjects reduces hepatic de novo lipogenesis, stimulates adipose tissue lipolysis, and increases hepatic glucose production by increasing gluconeogenesis.
Author CIOCIARO, DEMETRIO
MOCCIARO, GABRIELE
GASTALDELLI, AMALIA
PEZZICA, SAMANTHA
CARLI, FABRIZIA
TRIPATHY, DEVJIT
CHEN, XI
DEFRONZO, RALPH A.
Author_xml – sequence: 1
  givenname: XI
  surname: CHEN
  fullname: CHEN, XI
– sequence: 2
  givenname: FABRIZIA
  surname: CARLI
  fullname: CARLI, FABRIZIA
– sequence: 3
  givenname: SAMANTHA
  surname: PEZZICA
  fullname: PEZZICA, SAMANTHA
– sequence: 4
  givenname: GABRIELE
  surname: MOCCIARO
  fullname: MOCCIARO, GABRIELE
– sequence: 5
  givenname: DEMETRIO
  surname: CIOCIARO
  fullname: CIOCIARO, DEMETRIO
– sequence: 6
  givenname: AMALIA
  surname: GASTALDELLI
  fullname: GASTALDELLI, AMALIA
– sequence: 7
  givenname: RALPH A.
  surname: DEFRONZO
  fullname: DEFRONZO, RALPH A.
– sequence: 8
  givenname: DEVJIT
  surname: TRIPATHY
  fullname: TRIPATHY, DEVJIT
BookMark eNo9kMFKw0AQhhepYFs9-QILHiU6u5tsEm9StS0EC60Hb8skmcSUNom7jdC3d0tF5jCH-f5_4JuwUdu1xNitgAepVPxY5lIGSkOwWl-wsUhVGigZf47YGEDIQMRpfMUmzm0BQPsZs_pMP_HFsSdb74YCa9-5b5CvqRwKcvyF-Hv30_Gs6buaWnKN49iWfNkWltB5Yu5jPvR_bVq-INwdvo58M-RbKg7uml1WuHN087enbPP2-jFbBNlqvpw9Z0GhQwjKqBIyBZWoCASCQtClFlLlGnWVSIkqpTKKSi1RhAoxrKRGkRLkSaGFVlN2d27tbfc9kDuYbTfY1j80UidRlIYJgKfuz1RhO-csVaa3zR7t0QgwJ4_m5NF4M2a1Vr9DZ2ai
ContentType Journal Article
Copyright Copyright American Diabetes Association Jun 2022
Copyright_xml – notice: Copyright American Diabetes Association Jun 2022
DBID AAYXX
CITATION
K9.
NAPCQ
DOI 10.2337/db22-360-OR
DatabaseName CrossRef
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
DatabaseTitle CrossRef
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
DatabaseTitleList ProQuest Health & Medical Complete (Alumni)
CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1939-327X
ExternalDocumentID 10_2337_db22_360_OR
Genre Conference Proceeding
GroupedDBID ---
.55
.XZ
08P
0R~
18M
29F
2WC
354
4.4
53G
5GY
5RE
5RS
5VS
6PF
8R4
8R5
AAFWJ
AAQQT
AAWTL
AAYEP
AAYXX
ABOCM
ACGFO
ACGOD
ACPRK
ADBBV
AEGXH
AENEX
AERZD
AHMBA
AIAGR
AIZAD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BES
BTFSW
CITATION
CS3
DIK
DU5
E3Z
EBS
EDB
EMOBN
EX3
F5P
FRP
GX1
H13
HZ~
IAO
IEA
IHR
INH
INR
IOF
IPO
K2M
KQ8
L7B
M5~
O5R
O5S
O9-
OHH
OK1
OVD
P2P
PCD
Q2X
RHI
RPM
SJN
SV3
TDI
TEORI
TR2
VVN
W8F
WH7
WOQ
WOW
X7M
YFH
YHG
YOC
ZY1
~KM
K9.
NAPCQ
ID FETCH-LOGICAL-c640-d5f1290383501a03a06d6123b6a6f822a39ed55d62a143aa4f26a19e0b8c6163
ISSN 0012-1797
IngestDate Mon Jun 30 10:42:36 EDT 2025
Tue Jul 01 02:41:20 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue Supplement_1
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c640-d5f1290383501a03a06d6123b6a6f822a39ed55d62a143aa4f26a19e0b8c6163
Notes ObjectType-Conference Proceeding-1
SourceType-Scholarly Journals-1
content type line 14
PQID 2685594800
PQPubID 34443
ParticipantIDs proquest_journals_2685594800
crossref_primary_10_2337_db22_360_OR
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-06-01
20220601
PublicationDateYYYYMMDD 2022-06-01
PublicationDate_xml – month: 06
  year: 2022
  text: 2022-06-01
  day: 01
PublicationDecade 2020
PublicationPlace New York
PublicationPlace_xml – name: New York
PublicationTitle Diabetes (New York, N.Y.)
PublicationYear 2022
Publisher American Diabetes Association
Publisher_xml – name: American Diabetes Association
SSID ssj0006060
Score 2.3914666
Snippet Although the effect of glucagon on glucose metabolism has been well characterized, its effect on lipid metabolism, particularly lipolysis and de novo...
SourceID proquest
crossref
SourceType Aggregation Database
Index Database
SubjectTerms Adipose tissue
Diabetes
Gas chromatography
Glucagon
Gluconeogenesis
Glucose
Glucose metabolism
Lipid metabolism
Lipogenesis
Lipolysis
Liver
Mass spectroscopy
Metabolism
Palmitic acid
Plasma
Triglycerides
Title 360-OR: Hyperglucagonemia Reduces De Novo Lipogenesis and Increases Gluconeogenesis in Healthy Subjects
URI https://www.proquest.com/docview/2685594800
Volume 71
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELZgkRAXxFMsLMiHvaFAnnbCLaSFBGiLQpGqXiI7caoeNl1tuxz49cw4TpotPSxcoijpOJXny_ibycyYkHMgbCoMJbMcGbiWrzizIuVLS1XSEcJ1ea2b-kymLP3pf1kEi31MV1eX7OS78vfRupL_0SpcA71ilew_aLYfFC7AOegXjqBhON5Kxx6zrVmOTn0K7uQVpp-L1aZRF2sB81ZdY7bVSL2dbn5twPm-3KzQsK23JgcY-eIWfvEZs9Yb1d_V3a8wK0ybFYzTbIcUdjSI1h7u4zOIKyTpWGcQLPqwbBLn3zJNluOPebbMeux8Hy-XWRLrQCysAdN52t-azJIki_OZDt-j2Ng0DjGBCvBx-4Sqzvg6LnZD5UPjy50ByPRGpjoqWjjHzLvr6QYBlcQKBD3D-1Ws-3J_sLj1KYfg7KB4gcIFCBez_C655wJWcd-LUfa1X7_BpWsLl8zfbas6Ufj94Mk3eczNZVxzk_kj8tA4FTRuEfKY3FHNE3J_YtImnpJVO9gH-hdMqIEJHSmKMKEDmFCACe1hQg9gQtcNNTChHUyekR-fxvMktcwOG1bJfNuqghrDkF6IX5eF7QmbVdiORzLBamCOwotUFQQVcwXQaiH82mXCiZQtw5IBkX9OThp48AtCpc05r8tK-bzyy6AMgReXNXhvMmJRHfBTct7NVnHZtlEpjmjklJx1M1mY92xbuCwMsKmQbb-83SivyIM9_s7Iye7qWr0G6riTb7Sm_wCtu2lf
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=360-OR%3A+Hyperglucagonemia+Reduces+De+Novo+Lipogenesis+and+Increases+Gluconeogenesis+in+Healthy+Subjects&rft.jtitle=Diabetes+%28New+York%2C+N.Y.%29&rft.au=CHEN%2C+XI&rft.au=CARLI%2C+FABRIZIA&rft.au=PEZZICA%2C+SAMANTHA&rft.au=MOCCIARO%2C+GABRIELE&rft.date=2022-06-01&rft.issn=0012-1797&rft.volume=71&rft.issue=Supplement_1&rft_id=info:doi/10.2337%2Fdb22-360-OR&rft.externalDBID=n%2Fa&rft.externalDocID=10_2337_db22_360_OR
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0012-1797&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0012-1797&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0012-1797&client=summon